{"id":"ticagrelor-first","safety":{"commonSideEffects":[{"rate":"3–5","effect":"Bradycardia"},{"rate":"13–14","effect":"Dyspnea"},{"rate":"11–13","effect":"Bleeding (major and minor)"},{"rate":"2–3","effect":"Ventricular pauses"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor binds reversibly to the P2Y12 receptor on platelet surfaces, preventing ADP-mediated platelet activation and aggregation. This reduces thrombotic events in patients with acute coronary syndrome or a history of myocardial infarction. Unlike prodrug thienopyridines, ticagrelor is active without hepatic metabolism.","oneSentence":"Ticagrelor is a direct-acting P2Y12 receptor antagonist that inhibits platelet aggregation by blocking adenosine diphosphate (ADP) signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:42.576Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis"},{"name":"Chronic coronary disease for secondary prevention of cardiovascular events"}]},"trialDetails":[{"nctId":"NCT07495969","phase":"NA","title":"Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR）","status":"NOT_YET_RECRUITING","sponsor":"Feng Gao","startDate":"2026-04-01","conditions":"Symptomatic Non-acute Intracranial Artery Occlusion, Ischemic Stroke","enrollment":286},{"nctId":"NCT04654052","phase":"PHASE4","title":"VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación EPIC","startDate":"2021-07-02","conditions":"Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease","enrollment":634},{"nctId":"NCT06853535","phase":"PHASE3","title":"Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE","status":"RECRUITING","sponsor":"Sichuan Provincial People's Hospital","startDate":"2025-05-23","conditions":"Acute Ischemic Stroke, Clopidogrel Resistance","enrollment":5138},{"nctId":"NCT07268859","phase":"NA","title":"Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea","status":"RECRUITING","sponsor":"Acibadem University","startDate":"2025-03-15","conditions":"Acute Coronary Syndromes, Ticagrelor, Dyspnea","enrollment":110},{"nctId":"NCT06591377","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-08-10","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT03869268","phase":"PHASE4","title":"The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2019-04-24","conditions":"Acute Coronary Syndrome","enrollment":72},{"nctId":"NCT06591338","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-09-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT05380063","phase":"PHASE4","title":"Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting","status":"COMPLETED","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-02-14","conditions":"Coronary Artery Disease, Coronary Artery Bypass Grafting, Dual Antiplatelet Therapy","enrollment":2300},{"nctId":"NCT06318481","phase":"PHASE3","title":"TADCLOT- a Double Blind Randomized Controlled Trial","status":"COMPLETED","sponsor":"National Institute of Cardiovascular Diseases, Pakistan","startDate":"2024-02-19","conditions":"Stent Thrombosis, Myocardial Infarction, Acute","enrollment":2200},{"nctId":"NCT02733341","phase":"PHASE4","title":"The Effect of IV Cangrelor and Oral Ticagrelor Study","status":"COMPLETED","sponsor":"The Royal Wolverhampton Hospitals NHS Trust","startDate":"2016-07-21","conditions":"Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO)","enrollment":100},{"nctId":"NCT03551964","phase":"PHASE4","title":"Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2018-08-01","conditions":"Acute Myocardial Infarction, Cardiogenic Shock","enrollment":605},{"nctId":"NCT05329155","phase":"NA","title":"Early Administration of Heparin At FMC for PPCI of STEMI Patients","status":"COMPLETED","sponsor":"Renmin Hospital of Wuhan University","startDate":"2022-07-20","conditions":"STEMI, Primary PCI","enrollment":1145},{"nctId":"NCT06826144","phase":"NA","title":"Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracranial Aneurysms","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02-20","conditions":"Unruptured Intracranial Aneurysm, Infarction Cerebral","enrollment":84},{"nctId":"NCT06591390","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-02-09","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06591312","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-05-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06242145","phase":"PHASE3","title":"Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2023-01-01","conditions":"Ischemic Stroke","enrollment":580},{"nctId":"NCT06561867","phase":"PHASE3","title":"Ticagrelor Versus Cilostazol in Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-08-30","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06196047","phase":"PHASE3","title":"Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2023-12-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06202755","phase":"PHASE3","title":"Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-03-30","conditions":"Ischemic Stroke","enrollment":580},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05553613","phase":"PHASE3","title":"Ticagrelor Versus Clopidogrel in Ischemic Stroke","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-10-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06013020","phase":"PHASE4","title":"Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus","status":"RECRUITING","sponsor":"Zunyi Medical College","startDate":"2024-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":374},{"nctId":"NCT06254391","phase":"PHASE2","title":"Aspirin Dose Comparison in Elderly PCI Patients: 30mg vs. 75mg in Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2023-07-03","conditions":"Myocardial Infarction, Acute Coronary Syndrome","enrollment":40},{"nctId":"NCT06120725","phase":"PHASE3","title":"Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2021-09-01","conditions":"Ischemic Stroke","enrollment":580},{"nctId":"NCT04588727","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-15","conditions":"Cardiovascular Disease","enrollment":103},{"nctId":"NCT05116995","phase":"PHASE4","title":"Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients","status":"UNKNOWN","sponsor":"Nova Scotia Health Authority","startDate":"2021-11-01","conditions":"Thrombosis, Myocardial Infarction","enrollment":30},{"nctId":"NCT04634162","phase":"PHASE4","title":"PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-02-09","conditions":"Coronary Artery Disease","enrollment":22},{"nctId":"NCT05831462","phase":"PHASE1, PHASE2","title":"De-escalation of Ticagrelor in Post PPCI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-06-01","conditions":"Ticagrelor","enrollment":400},{"nctId":"NCT04718025","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2022-02-07","conditions":"STEMI, NSTEMI, Unstable Angina","enrollment":4500},{"nctId":"NCT03251859","phase":"PHASE3","title":"Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2017-08-11","conditions":"Myocardial Infarction","enrollment":52},{"nctId":"NCT04944615","phase":"NA","title":"To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.","status":"RECRUITING","sponsor":"CCRF Inc., Beijing, China","startDate":"2022-10-21","conditions":"Chronic Total Occlusion of Coronary Artery","enrollment":1448},{"nctId":"NCT05779059","phase":"PHASE3","title":"Prasugrel Or Ticagrelor De-escalation in NSTE-ACS","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2023-04-01","conditions":"Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Unstable Angina","enrollment":50},{"nctId":"NCT04568083","phase":"","title":"Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-09-25","conditions":"Myocardial Infarction (MI)","enrollment":7035},{"nctId":"NCT02251249","phase":"PHASE4","title":"Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study.","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-12-08","conditions":"Impairment of Gastric Emptying, Acute Phase of Myocardial Infarction","enrollment":23},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT05080478","phase":"","title":"Effects of P2Y12 Receptor Inhibitors on Central and Peripheral Chemoreceptors' Sensitivity","status":"UNKNOWN","sponsor":"Wroclaw Medical University","startDate":"2018-11-01","conditions":"Dyspnea","enrollment":50},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT04995159","phase":"NA","title":"Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System","status":"NOT_YET_RECRUITING","sponsor":"Lepu Medical Technology (Beijing) Co., Ltd.","startDate":"2021-09","conditions":"Coronary Heart Disease","enrollment":2150},{"nctId":"NCT04962451","phase":"PHASE4","title":"Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2017-09-01","conditions":"Cerebrovascular Accident, Cerebrovascular Accident, Acute","enrollment":13000},{"nctId":"NCT02341729","phase":"PHASE4","title":"Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2015-03","conditions":"Acute Coronary Syndrome","enrollment":40},{"nctId":"NCT04826497","phase":"PHASE4","title":"Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction","status":"UNKNOWN","sponsor":"Xuzhou Central Hospital","startDate":"2021-04","conditions":"Coronary Heart Disease","enrollment":80},{"nctId":"NCT04754789","phase":"PHASE3","title":"Effect of Upstream Treatment With High Intensity Statin on the Outcomes of STMI Patients Treated With PPCI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-02-20","conditions":"ST Elevation Myocardial Infarction","enrollment":160},{"nctId":"NCT04570345","phase":"PHASE4","title":"3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI","status":"UNKNOWN","sponsor":"Dong-A University","startDate":"2021-01-01","conditions":"ST Elevation Myocardial Infarction","enrollment":1002},{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT02701140","phase":"PHASE2, PHASE3","title":"Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease","status":"COMPLETED","sponsor":"Italo Porto","startDate":"2016-06","conditions":"Myocardial Ischemia","enrollment":58},{"nctId":"NCT04630288","phase":"","title":"Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud","startDate":"2019-07-02","conditions":"Acute Coronary Syndromes","enrollment":1900},{"nctId":"NCT02271022","phase":"","title":"Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-17","conditions":"Acute Coronary Syndromes","enrollment":2000},{"nctId":"NCT02506140","phase":"PHASE2, PHASE3","title":"Platelet Reactivity in Acute Non-disabling Cerebrovascular Events","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2015-08","conditions":"Stroke, Ischemic Attack, Transient","enrollment":675},{"nctId":"NCT02531165","phase":"NA","title":"Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2015-09","conditions":"Acute Myocardial Infarction","enrollment":38},{"nctId":"NCT04338919","phase":"NA","title":"Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2020-04-14","conditions":"Acute Coronary Syndrome, Percutaneous Coronary Intervention","enrollment":2020},{"nctId":"NCT04369534","phase":"PHASE4","title":"Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction","status":"COMPLETED","sponsor":"University of Zagreb","startDate":"2015-12-01","conditions":"Acute Coronary Syndrome, STEMI, NSTEMI - Non-ST Segment Elevation MI","enrollment":120},{"nctId":"NCT02429271","phase":"PHASE3","title":"A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study","status":"COMPLETED","sponsor":"Hellenic Cardiovascular Research Society","startDate":"2015-08","conditions":"Myocardial Infarction, ST Segment Elevation Myocardial Infarction (STEMI)","enrollment":336},{"nctId":"NCT02407314","phase":"PHASE4","title":"Ticagrelor and Peripheral Arterial Disease","status":"TERMINATED","sponsor":"Arkansas Heart Hospital","startDate":"2015-06","conditions":"Peripheral Arterial Disease","enrollment":26},{"nctId":"NCT02330640","phase":"PHASE4","title":"A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2016-01","conditions":"Antiplatelet Therapy of Coronary Artery Bypass","enrollment":137},{"nctId":"NCT02513004","phase":"PHASE4","title":"Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel","status":"UNKNOWN","sponsor":"Yongjian Wu","startDate":"2015-06","conditions":"Coronary Disease","enrollment":60},{"nctId":"NCT02244710","phase":"NA","title":"EndoTic - Endothelium and Ticagrelor","status":"COMPLETED","sponsor":"Fundación Investigación Sanitaria en León","startDate":"2015-03","conditions":"Acute Coronary Syndrome (ACS)","enrollment":109},{"nctId":"NCT01852214","phase":"NA","title":"Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes","status":"COMPLETED","sponsor":"University of Florida","startDate":"2013-02","conditions":"Diabetes Mellitus, Coronary Artery Disease","enrollment":50},{"nctId":"NCT02580149","phase":"PHASE4","title":"The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment","status":"COMPLETED","sponsor":"Michael Wolzt, Prof. MD","startDate":"2015-10","conditions":"Ischemia","enrollment":24},{"nctId":"NCT02071966","phase":"PHASE4","title":"Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS","status":"TERMINATED","sponsor":"Catholic University of the Sacred Heart","startDate":"2012-11","conditions":"Non ST Segment Elevation Acute Coronary Syndrome","enrollment":55},{"nctId":"NCT02457130","phase":"PHASE4","title":"Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)","status":"UNKNOWN","sponsor":"Spanish Society of Cardiology","startDate":"2015-04","conditions":"Coronary Artery Disease, Diabetes Mellitus. Type 2","enrollment":30},{"nctId":"NCT01276275","phase":"","title":"Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-01","conditions":"Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout","enrollment":7200},{"nctId":"NCT02469740","phase":"PHASE4","title":"Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI","status":"COMPLETED","sponsor":"University Hospital of Limerick","startDate":"2015-07","conditions":"Myocardial Ischemia, Coronary Artery Disease, Endothelial Dysfunction","enrollment":61},{"nctId":"NCT01994941","phase":"PHASE4","title":"Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2013-08","conditions":"Acute Coronary Syndrome","enrollment":133},{"nctId":"NCT02428374","phase":"PHASE4","title":"Role of Immune Responses After Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"Federal University of São Paulo","startDate":"2015-05","conditions":"Myocardial Fibrosis","enrollment":300},{"nctId":"NCT02459288","phase":"PHASE4","title":"Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients","status":"UNKNOWN","sponsor":"Ping-Yen Liu","startDate":"2014-01","conditions":"Acute Coronary Syndrome, Chronic Kidney Disease, End-Stage Renal Disease","enrollment":80},{"nctId":"NCT01864005","phase":"PHASE4","title":"A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-05","conditions":"Non-ST or ST Elevation Acute Coronary Syndromes","enrollment":60},{"nctId":"NCT02435797","phase":"PHASE4","title":"Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction","status":"UNKNOWN","sponsor":"Xuzhou Central Hospital","startDate":"2015-04","conditions":"Coronary Heart Disease","enrollment":100},{"nctId":"NCT02406911","phase":"PHASE3","title":"Ticagrelor and Anti-inflammatory Effects","status":"UNKNOWN","sponsor":"Kyunghee University Medical Center","startDate":"2015-02","conditions":"Chronic Kidney Disease","enrollment":25},{"nctId":"NCT02394145","phase":"PHASE3","title":"Genotype and Platelet Reactivity in Patients on Hemodialysis","status":"UNKNOWN","sponsor":"Kyunghee University Medical Center","startDate":"2009-09","conditions":"Chronic Kidney Disease","enrollment":20},{"nctId":"NCT01992523","phase":"PHASE3","title":"Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )","status":"COMPLETED","sponsor":"David Antoniucci","startDate":"2013-11","conditions":"Acute Coronary Syndrome, Adverse Reaction to Antiplatelet Agent","enrollment":82},{"nctId":"NCT01805570","phase":"PHASE4","title":"Rapid Activity of Platelet Inhibitor Drugs Study 2","status":"COMPLETED","sponsor":"David Antoniucci","startDate":"2012-11","conditions":"Myocardial Infarction","enrollment":50},{"nctId":"NCT02163954","phase":"PHASE3","title":"ONSET and OFFSET of Ticagrelor in ESRD","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2013-01","conditions":"Chronic Kidney Disease","enrollment":16},{"nctId":"NCT01543932","phase":"PHASE3","title":"High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2012-07","conditions":"Coronary Artery Disease","enrollment":81},{"nctId":"NCT00721448","phase":"PHASE1","title":"An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Pharmacokinetics","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":615,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["T-C"],"phase":"marketed","status":"active","brandName":"Ticagrelor first","genericName":"Ticagrelor first","companyName":"Ping-Yen Liu","companyId":"ping-yen-liu","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ticagrelor is a direct-acting P2Y12 receptor antagonist that inhibits platelet aggregation by blocking adenosine diphosphate (ADP) signaling. Used for Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis, Chronic coronary disease for secondary prevention of cardiovascular events.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}